Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
about
Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signalingThe elements of life and medicinesYin-yang and Zheng: Exported from Chinese medicine.Metabolism, toxicity and anticancer activities of arsenic compounds.Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to DarinaparsinGlutathione S-conjugates as prodrugs to target drug-resistant tumors.Multivalency in the inhibition of oxidative protein folding by arsenic(III) species.Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like CellsNMFBFS: A NMF-Based Feature Selection Method in Identifying Pivotal Clinical Symptoms of Hepatocellular Carcinoma.Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometryDual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen.Anticancer activity of metal complexes: involvement of redox processes.Cellular redox pathways as a therapeutic target in the treatment of cancer.Metal-based drugs that break the rules.The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells.Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.Deciphering the molecular events during arsenic induced transcription signal cascade activation in cellular milieu.Activation of the Nrf2 Signaling Pathway Involving KLF9 Plays a Critical Role in Allicin Resisting Against Arsenic Trioxide-Induced Hepatotoxicity in Rats.
P2860
Q27312382-7E7DA752-88B1-461B-BF7B-02AB61BFD634Q28649323-1B74D1BA-4ACF-413E-9891-86F2159D4A5AQ30385603-E063F9E1-F851-48CF-823A-1FF2B18FEFEEQ33618916-22F2E04B-22AA-4C97-83E7-EAC9FE840266Q33637102-918DC5D6-3AAB-4C49-A1D1-8AB0218D4A91Q34024771-1D952704-1E8E-4435-AF34-571B679EAA7BQ35001166-7AE7869F-4377-4229-BDE7-3F64A50C282EQ35773665-C7D995F6-CC3E-4801-B056-48E156D2822FQ36249939-F75367DD-286A-4FB5-A1D5-A2B5E48E2393Q36566386-4D948F88-8C9C-498F-A43B-304432137538Q37317562-6A6C0203-8A84-4A06-9300-606165E4C6A8Q37833099-83447100-EF71-4181-AE78-937274E740E0Q37910897-200E722A-27AF-4EF5-9922-D974319E1311Q38714812-62700C17-6EB5-43DE-A12C-42E90C54635CQ38938902-81C4035B-D7D1-48DC-8895-E9929391B197Q41069547-48F1FD9A-0D2A-4821-B3E7-82653FE6E941Q47397630-93400304-23AA-41FB-8051-502B53EB3E8AQ51550506-493F1813-0794-4C88-8F67-8388C0349FC6
P2860
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
@en
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
@nl
type
label
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
@en
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
@nl
prefLabel
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
@en
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
@nl
P2093
P2860
P1476
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
@en
P2093
Andrew X Zhu
Barry Rosenzweig
Charles Henderson
Giovanni Abbadessa
Haobin Chen
Howard Hochster
Jennifer Wu
Jonathan Lewis
Lawrence S Blaszkowsky
P2860
P2888
P304
P356
10.1007/S10637-009-9286-9
P577
2009-06-30T00:00:00Z
P6179
1001960219